Qingdao Weilan Biological Co., Ltd. 2026 First Quarter Report
Securities code: 603739 Securities abbreviation: Qingdao Weilan Biotechnology Co., Ltd.
2026 First Quarter Report
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder
The company's board of directors, directors and senior managers guarantee that the contents of the quarterly report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) guarantee that the financial information in the quarterly report is true, accurate and complete.
Are the first quarter financial statements audited?
□Yes √No
1. Main financial data
(1) Main accounting data and financial indicators
Unit: Yuan Currency: RMB
Items during this reporting period compared with the same period last year This reporting period compared with the same period last year
Increase or decrease (%) operating income 345,050,139.43 310,197,929.93 11.24Total profit 32,230,638.10 24,373,444.84 32.24Net profit attributable to shareholders of listed companies 17,867,737.01 9,576,827.68 86.57 Deductions attributable to shareholders of listed companies are not
11,349,597.73 5,259,509.61 115.79 Net profit from recurring gains and losses
Net cash flow generated from operating activities 18,262,588.29 7,617,106.76 139.76 Basic earnings per share (yuan/share) 0.07 0.04 75.00 Diluted earnings per share (yuan/share) 0.07 0.04 75.00 Weighted average return on equity (%) 1.01 0.55 An increase of 0.46 percentage points at the end of the reporting period compared with the end of the previous year. The end of the reporting period at the end of the previous year.
Total assets at the end of the year (%) 3,076,136,009.03 3,039,659,299.32 1.20
1/10
Qingdao Weilan Biological Co., Ltd. 2026 First Quarter Report
Owners attributable to shareholders of listed companies
1,799,752,986.63 1,782,521,319.49 0.97 Equity
(2) Non-recurring profit and loss items and amounts
√Applicable □Not applicable
Unit: Yuan Currency: RMB
Non-recurring gains and losses items Amount for the current period Description of gains and losses from disposal of non-current assets, including accrued asset deductions
7,242.26 offset portion of value provision
Government subsidies are included in the current profit and loss, but are not related to the company’s normal operations.
Closely related to business operations, in compliance with national policies and regulations, and in accordance with
5,251,176.96 to enjoy the determined standards and have a continuous impact on the company’s profits and losses
Except for government subsidies
Except for effective hedging related to the company’s normal business operations
In addition to business, non-financial enterprises hold financial assets and financial liabilities
-Profits and losses from changes in fair value of debt and disposal financing
Profit and loss arising from assets and financial liabilities
The proportion of funds collected from non-financial enterprises included in the current profit and loss
-Fees
Gains and losses from entrusting others to invest or manage assets 3,396,688.36 Gains and losses from external entrusted loans - due to force majeure factors, such as natural disasters
-Loss of various assets
Reversal of impairment provision for receivables subject to separate impairment test - Enterprises obtain investments from subsidiaries, associates and joint ventures
If the capital cost is less than the investment, the investee shall be entitled to the income generated by identifying the fair value of the net assets.
The balance sheet of subsidiaries resulting from business combinations under common control from the beginning to the end of the period
-Net profit and loss for the current period on the date of merger
Gains and losses from non-monetary asset exchanges - Gains and losses from debt restructuring - One time an enterprise occurs because relevant operating activities are no longer sustainable
- Sexual expenses, such as expenses for placement of employees, etc.
Due to adjustments in taxation, accounting and other laws and regulations, the current period's losses
- One-time impact of benefits
The shares recognized in one go due to the cancellation or modification of the equity incentive plan
- payment of fees
For cash-settled share-based payment, on the vesting date
After that, the gains and losses arising from changes in the fair value of employee compensation payable
2/10
Qingdao Weilan Biological Co., Ltd. 2026 First Quarter Report
Investment properties that adopt the fair value model for subsequent measurement
-
Gains and losses arising from changes in fair value of real estate
Gains from transactions where the transaction price appears to be unfair -
Contingencies unrelated to the company's normal business operations arise
-
Profit and loss
Custody fee income from entrusted operations -
Other non-operating income and expenses other than the above items -6,055.38
Other profit and loss items that meet the definition of non-recurring profit and loss -
Less: Income tax impact 1,767,920.75
Amount of impact on minority shareholders’ equity (after tax) 362,992.17
Total 6,518,139.28
If the company determines items not listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as non-recurring gains and losses and is significant in amount, and if it defines the non-recurring gain or loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure by Companies that Offer Securities to the Public - Non-recurring Gains and Losses" as recurring gains and losses, the reasons should be explained.
□Applicable √Not applicable
(3) Changes in main accounting data and financial indicators and reasons
√Applicable □Not applicable
Change ratio
Project name Main reason
(%)
Total profit 32.24 Mainly due to the increase in sales of the company’s microecology and enzyme preparation products, resulting in net profit attributable to shareholders of the listed company 86.57 Mainly due to the increase in sales of the company’s microecology and enzyme preparation products, net profit attributable to shareholders of the listed company after deduction of non-profit
115.79 Mainly due to the net profit from recurring gains and losses caused by the increase in sales of the company’s microecological and enzyme preparation products
Mainly due to the increase in the company's revenue, the product sales received increased the net cash flow generated from operating activities 139.76
cause
Basic earnings per share (yuan/share) 75.00 Mainly due to the increase in sales of the company's microecology and enzyme preparation products, diluted earnings per share (yuan/share) 75.00 Mainly due to the increase in sales of the company's microecology and enzyme preparation products
2. Shareholder information
(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders
Unit: Share
Total number of preference shareholders whose voting rights were restored at the end of the reporting period
Total number of common shareholders at the end of the reporting period 20,179 Not applicable (if any)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
3/10
Qingdao Weilan Biological Co., Ltd. 2026 First Quarter Report
Staking, marking or freezing status
Shareholding Ratio Holding Restricted Coupons
Name of shareholder Nature of shareholder Number of shares held
Example (%) Number of shares
shares
Quantity
Status
Qingdao Kangdien Industrial Co., Ltd. Domestic non-state-owned legal person 112,407,400 44.42 0 None 0Tibet Sizhuang Investment Consulting Co., Ltd. Domestic non-state-owned legal person 17,775,520 7.03 0 None 0Tibet Shancheng Investment Consulting Co., Ltd. Domestic non-state-owned legal person 17,775,520 7.03 0 None 0Jia Deqiang Domestic natural person 7,103,760 2.81 0 Pledge 1,700,000Chen Gang Domestic natural person 3,709,560 1.47 0 None 0Beijing Kangyu Technology Co., Ltd. Domestic non-state-owned legal person 3,480,000 1.38 0 None 0Wu Jinyuan Domestic natural person 3,350,580 1.32 0 None 0 Zheshang Bank Co., Ltd. - National
Thailand China Securities Livestock Breeding Trading Open Others 1,685,700 0.67 0 None 0-type Index Securities Investment Fund
Goldman Sachs International - Own funds Overseas legal person 1,610,538 0.64 0 None 0 Shanghai Bingqing Private Equity Fund Management Co., Ltd.
Company - Bingqing Selection No. 1 Private Equity Certificate Others 1,188,000 0.47 0 None 0 Bond Investment Fund
Shareholding status of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing)
Type and quantity of shares
Name of shareholder Number of shares held without selling restrictions
Share Type Quantity
Qingdao Kangdien Industrial Co., Ltd. 112,407,400 RMB ordinary shares 112,407,400 Tibet Strong Investment Consulting Co., Ltd. 17,775,520 RMB ordinary shares 17,775,520 Tibet Shancheng Investment Consulting Co., Ltd. 17,775,520 RMB ordinary shares 17,775,520 Jia Deqiang 7,103,760 RMB ordinary shares 7,103,760 Chen Gang 3,709,560 RMB ordinary shares 3,709,560 Beijing Kangyu Technology Co., Ltd. 3,480,000 RMB ordinary shares 3,480,000 Wu Jinyuan 3,350,580 RMB ordinary shares 3,350,580 Zheshang Bank Co., Ltd. - National
Thai China Securities Livestock Breeding Trading Open 1,685,700 RMB ordinary shares 1,685,700 Index Securities Investment Fund
Goldman Sachs International - Own funds 1,610,538 RMB ordinary shares 1,610,538 Shanghai Bingqing Private Equity Fund Management Co., Ltd.
Company - Bingqing Selection No. 1 Private Equity Certificate 1,188,000 RMB ordinary shares 1,188,000 Bond Investment Fund
- The above-mentioned shareholders of Tibet Shancheng Investment Consulting Co., Ltd., Tibet Strong Investment Consulting Co., Ltd., and Qingdao Kangdien Industrial are related or acting in concert
A limited company constitutes a person acting in concert;
Description of movement
- Beijing Kangyu Technology Co., Ltd. is a company controlled by Chen Gang.
Top 10 shareholders and top 10 unlimited
Selling shareholders participate in margin financing and securities lending and refinancing Not applicable
Description of communication business situation (if any)
4/10
Qingdao Weilan Biological Co., Ltd. 2026 First Quarter Report
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
□Applicable √Not applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□Applicable √Not applicable
3. Other reminders
Investors need to be reminded of other important information regarding the company’s operations during the reporting period.
□Applicable √Not applicable
4. Quarterly Financial Statements
(1) Types of audit opinions
□Applicable √Not applicable
(2) Financial statements
Consolidated Balance Sheet
March 31, 2026
Prepared by: Qingdao Weilan Biological Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Item March 31, 2026 Current assets on December 31, 2025:
Monetary funds 230,012,716.89 244,157,573.25 Trading financial assets 267,372,201.37 224,866,908.03 Notes receivable 14,549,327.98 26,533,287.10 Accounts receivable 387,219,949.05 379,015,180.19 Receivables financing 4,624,088.53 3,722,769.03 Prepayments 43,748,059.83 10,700,133.69 Other receivables 45,842,110.42 41,970,018.07 Including: interest receivable - -
Dividends receivable - - Inventory 230,518,458.27 226,369,014.44 Including: data resources - contract assets - assets held for sale - non-current assets due within one year 7,000,000.00 9,000,000.00 Other current assets 7,097,301.77 12,284,299.25
Total current assets 1,237,984,214.11 1,178,619,183.05 Non-current assets:
5/10
Qingdao Weilan Biological Co., Ltd. 2026 First Quarter Report
Debt investments 5,000,000.00 5,000,000.00 Other debt investments - Long-term receivables - Long-term equity investments 63,853,720.93 63,934,462.23 Other equity instrument investments 5,904,929.82 7,315,229.82 Other non-current financial assets - Investment real estate - Fixed assets 1,460,620,932.40 1,486,115,581.93 Construction in progress 31,319,741.69 37,395,397.76 Right-of-use assets - intangible assets 129,287,228.74 126,722,253.28 Including: data resources - development expenditures - - in which: data resources - goodwill 84,202,475.98 84,202,475.98 Long-term deferred expenses 1,465,299.68 1,264,043.17 Deferred income tax assets 24,486,076.70 23,554,298.22 Other non-current assets 32,011,388.98 25,536,373.88 Total non-current assets 1,838,151,794.92 1,861,040,116.27
Total assets 3,076,136,009.03 3,039,659,299.32 Current liabilities:
Short-term borrowings 620,433,138.62 582,874,900.68 Trading financial liabilities - Notes payable 3,850,000.00 1,480,000.00 Accounts payable 211,953,502.19 192,933,507.31 Advance receipts - Contract liabilities 22,721,547.39 14,247,030.44 Employee benefits payable 19,270,090.30 36,266,569.56 Taxes payable 17,443,856.29 17,543,138.74 Other payables 118,865,200.17 110,751,834.17 Including: interest payable - -
Dividends payable - - Liabilities held for sale - Non-current liabilities due within one year 26,020,325.15 36,117,905.05 Other current liabilities 14,869,986.46
Total current liabilities 1,040,557,660.10 1,007,084,872.41 Non-current liabilities:
Long-term borrowings 50,057,715.34 59,787,180.56 Bonds payable - including: preferred shares -
Perpetual Debt -Lease Liabilities -
6/10
Qingdao Weilan Biological Co., Ltd. 2026 First Quarter Report
Long-term payables - - Estimated liabilities 1,109,869.60 1,109,869.60 Deferred income 56,089,976.79 59,579,262.09 Deferred income tax liabilities 2,208,707.57 1,378,499.64 Other non-current liabilities - Total non-current liabilities 109,466,269.30 121,854,811.89
Total liabilities 1,150,023,929.41 1,128,939,684.30 Owners’ equity (or shareholders’ equity):
Paid-in capital (or equity) 253,028,866.00 253,028,866.00 Other equity instruments - including: preference shares -
Perpetual bonds - Capital reserve 702,898,795.16 702,898,795.16 Less: treasury shares - Other comprehensive income -15,167,353.92 -14,810,179.38 Special reserves - Surplus reserves 60,751,469.52 60,751,469.52 General risk reserves - Undistributed profits 798,241,209.87 780,652,368.19 Total owners’ equity (or shareholders’ equity) attributable to the parent company 1,799,752,986.63 1,782,521,319.49 Minority shareholders’ equity 126,359,092.99 128,198,295.53 Total owners’ equity (or shareholders’ equity) 1,926,112,079.62 1,910,719,615.02
Total liabilities and owners’ equity (or shareholders’ equity) 3,076,136,009.03 3,039,659,299.32
Person in charge of the company: Chen Gang Person in charge of accounting work: Qiao Piyuan Person in charge of the accounting department: Li Hailiang
consolidated income statement
January-March 2026
Prepared by: Qingdao Weilan Biological Co., Ltd.
Unit: Yuan Currency: RMB Audit type: Unaudited
Project First Quarter of 2026 First Quarter of 2025
Total operating income 345,050,139.43 310,197,929.93 Including: operating income 345,050,139.43 310,197,929.93
Total operating costs 319,210,567.09 293,945,014.79 Including: operating costs 192,439,618.52 172,593,365.91 Taxes and surcharges 4,067,645.58 3,400,130.96 Sales expenses 50,068,547.17 49,401,628.10 Administrative expenses 37,630,713.71 35,652,170.83 Research and development expenses 30,165,671.63 28,494,054.14 Financial expenses 4,838,370.48 4,403,664.85 Including: interest expenses 5,372,144.35 4,282,179.30
7/10
Qingdao Weilan Biological Co., Ltd. 2026 First Quarter Report
Interest income -49,737.52 -147,205.94 plus: other income 5,251,667.38 4,247,123.77 Investment income (losses are listed with "-") 3,315,947.06 1,661,922.50 Including: investment income from associates and joint ventures -Exchange income (losses are listed with "-") -Income from changes in fair value (losses are listed with "-") -1,980.00 495.00 Credit impairment losses (losses are listed with "-") -2,176,156.15 2,258,789.16 Asset impairment losses (losses are listed with "-") 469.59 167,960.88
Asset disposal income (losses are listed with "-") -69.00 -
Operating profit (losses are listed with "-") 32,229,451.22 24,589,206.45 plus: non-operating income 30,035.69 218,331.98 minus: non-operating expenses 28,848.81 434,093.59
Total profits (total losses are listed with "-") 32,230,638.10 24,373,444.84 Less: income tax expenses 6,778,651.06 7,787,082.66
Net profit (net loss is listed with "-") 25,451,987.04 16,586,362.18
(1) Classification by business continuity
Net profit from continuing operations (net loss is listed with "-") 25,451,987.04 16,586,362.18
Net profit from discontinued operations (net loss is listed with "-")
(2) Classification according to ownership ownership
Net profit attributable to shareholders of the parent company (net losses are listed with "-") 17,867,737.01 9,576,827.68
Profit and loss of minority shareholders (net loss is listed with "-") 7,584,250.03 7,009,534.50
Net amount of other comprehensive income after tax -480,627.11 -
(1) Net after-tax other comprehensive income attributable to owners of the parent company -357,174.54 -
Other comprehensive income that cannot be reclassified into profit or loss - (1) Changes in remeasurement of defined benefit plans -357,174.54 -
Other comprehensive income that will be reclassified into profit and loss -357,174.54 - (1) Translation difference of foreign currency financial statements -357,174.54 -
(2) Net after-tax other comprehensive income attributable to minority shareholders -123,452.57
- Total comprehensive income 24,971,359.93 16,586,362.18
(1) Total comprehensive income attributable to owners of the parent company 17,510,562.47 9,576,827.68
(2) Total comprehensive income attributable to minority shareholders 7,460,797.46 7,009,534.50
8. Earnings per share:
(1) Basic earnings per share (yuan/share) 0.07 0.04
(2) Diluted earnings per share (yuan/share) 0.07 0.04
If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0 yuan, and the net profit realized by the merged party in the previous period is: 0 yuan.
Person in charge of the company: Chen Gang Person in charge of accounting work: Qiao Piyuan Person in charge of the accounting department: Li Hailiang
Consolidated Cash Flow Statement
January-March 2026
Prepared by: Qingdao Weilan Biological Co., Ltd.
8/10
Qingdao Weilan Biological Co., Ltd. 2026 First Quarter Report
Unit: Yuan Currency: RMB Audit type: Unaudited
Project First Quarter of 2026 First Quarter of 2025
1. Cash flow generated from operating activities:
Cash received from selling goods and providing services 394,950,690.68 376,443,662.80 Tax refunds received 2,931,042.45 1,665,440.61 Cash received from other operating activities 7,649,391.36 6,416,605.26
Subtotal of cash inflows from operating activities 405,531,124.49 384,525,708.67 Cash paid for purchasing goods and receiving services 215,303,453.73 206,020,731.88 Cash paid to and for employees 76,564,018.33 77,034,647.91 Various taxes paid 22,111,328.15 26,296,269.33 Other cash paid related to operating activities 73,289,735.99 67,556,952.79 Subtotal of cash outflows from operating activities 387,268,536.20 376,908,601.91
Net cash flow generated from operating activities 18,262,588.29 7,617,106.76
2. Cash flow generated from investing activities:
Cash received from recovery of investment 11,073,189.59 - Cash received from investment income - Disposal of fixed assets, intangible assets and other long-term assets
2,714.00 Net cash recovered
Net cash received from disposal of subsidiaries and other business units
-Uh
Other cash received related to investing activities 65,600,000.00 242,600,000.00
Subtotal of cash inflows from investing activities 76,673,189.59 242,602,714.00 Purchase and construction of fixed assets, intangible assets and other long-term assets
14,770,042.91 41,340,500.86 Cash paid
Cash paid for investments - Net cash paid to acquire subsidiaries and other business units
-Uh
Other cash payments related to investing activities 100,195,230.00 284,100,495.00 Subtotal cash outflows from investing activities 114,965,272.91 325,440,995.86
Net cash flow generated from investing activities -38,292,083.32 -82,838,281.86
3. Cash flow generated from financing activities:
Cash received from investment 780,000.00 Including: cash received by subsidiaries from investment from minority shareholders
780,000.00 gold
Cash received from borrowings 136,660,015.22 139,470,088.29 Cash received from other financing activities -
Subtotal of cash inflows from financing activities 136,660,015.22 140,250,088.29 Cash paid to repay debts 121,184,343.31 60,050,000.00 Cash paid to distribute dividends, profits or pay interest 13,005,518.24 13,567,661.79 of which: dividends and profits paid by subsidiaries to minority shareholders
9,300,000.00 9,300,000.00 profit
Other cash payments related to financing activities -
9/10
Qingdao Weilan Biological Co., Ltd. 2026 First Quarter Report
Subtotal of cash outflows from financing activities 134,189,861.55 73,617,661.79
Net cash flow generated from financing activities 2,470,153.67 66,632,426.50
The impact of exchange rate changes on cash and cash equivalents -
Net increase in cash and cash equivalents -17,559,341.36 -8,588,748.60
Add: Balance of cash and cash equivalents at the beginning of the period 235,039,077.25 233,326,458.32
- Balance of cash and cash equivalents at the end of the period 217,479,735.89 224,737,709.72
Person in charge of the company: Chen Gang Person in charge of accounting work: Qiao Piyuan Person in charge of the accounting department: Li Hailiang
(3) The first implementation of new accounting standards or standard interpretations starting in 2026 will involve adjustments to the financial statements at the beginning of the year of first implementation.
□Applicable √Not applicable
Announcement hereby
Board of Directors of Qingdao Weilan Biological Co., Ltd. April 24, 2026
10/10